ODI Pharma Announces Directed Share Issue
ODI Pharma has announced a new directed share issue to raise capital efficiently.
Sammanfattning
ODI Pharma is set to conduct a directed share issue to swiftly secure capital, addressing immediate financial needs and facilitating market expansion.
ODI Pharma, a key player in the European medical cannabis market, has announced a strategic move to conduct a directed share issue. This decision aims to increase the company's share capital by SEK 70,769.24 through the issuance of 1,769,231 new shares at an issue price of SEK 0.65 per share, and an additional SEK 25,846.16 through 646,154 shares at SEK 1.30 per share. This move is designed to address immediate capital needs and facilitate the company's ongoing expansion in the competitive medical cannabis sector.
The directed share issue is a strategic decision by ODI Pharma's Board of Directors, allowing the company to raise necessary funds in a time-efficient manner, avoiding the complexities and higher costs associated with a traditional rights issue. The board has emphasized that this approach is more aligned with the company's immediate financial needs and is beneficial given the current market conditions.
Investors Niclas Kappelin and Volker Wiederrich, along with Derek Simmross and CEO Jan-Mark Edewaard, are set to participate in this share issue, reflecting confidence in ODI Pharma's strategic direction. The subscription price represents a significant discount to the market price, a reflection of negotiations and prevailing market conditions.
For potential investors and current shareholders, this move is indicative of ODI Pharma's proactive approach to capital management and market positioning. By opting for a directed share issue, the company not only addresses its immediate capital requirements but also strengthens its financial base to support future growth initiatives in the European medical cannabis market.
Given the strategic nature of this capital raise and the potential for growth in the medical cannabis sector, investors might consider holding their positions or potentially buying shares to capitalize on ODI Pharma's future prospects. The company's focus on innovation and market expansion in Poland and Europe at large positions it well for long-term success.
Källa
Sammanfattning
Shareholders wishing to participate in ODI Pharma AB's General Meeting must be registered with Euroclear Sweden AB by June 17, 2025, and notify the company by June 23, 2025, with their details. Nominee-registered shareholders must ensure their shares are registered in their own name by June 19, 2025. Proxies must bring written authorization and relevant documents to the meeting. The company has 15,915,034 shares and no own shares. The meeting agenda includes opening the meeting, electing a chairman, approving the voting list, certifying the minutes, confirming the meeting's validity, approving the agenda, and discussing the Board's proposals for directed share issues. The Board proposes two directed share issues: one to increase capital by SEK 70,769.24 with 1,769,231 new shares at SEK 0.65 each, and another to increase capital by SEK 25,846.16 with 646,154 new shares at SEK 1.30 each. These issues are aimed at specific investors and require a 90% approval from shareholders. The Board justifies these directed issues due to current market conditions, immediate capital needs, and lower costs compared to a rights issue. Personal data will be used for meeting registration and documentation. Relevant documents and proposals will be available at the company's office and website two weeks before the meeting. Shareholders can request additional information as per Swedish law. ODI Pharma focuses on distributing medical cannabis in Europe, particularly in Poland, with an emphasis on high-quality products and industry partnerships.
